To further determine whether the combination of BMS-911543 and a TKI had synergistic or addictive effect, we performed viability assays on CD34+ CML cells with graded doses of BMS-911543 and DA, alone or in combination, for 72 hours. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.